BeiGene

+$4.40 (+1.41%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BeiGene and other ETFs, options, and stocks.

About BGNE

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).

CEO
John V. Oyler
Employees
5,300
Headquarters
Beijing, Beijing
Founded
2010

BGNE Key Statistics

Market Cap
32.23B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
478.77K
High Today
$318.35
Low Today
$309.39
Open Price
$310.00
Volume
250.14K
52 Week High
$388.97
52 Week Low
$205.29

BGNE Earnings

-$6.39
-$4.03
-$1.67
$0.69
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Aug 13, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure